Anti-inflammatory therapies for bronchopulmonary dysplasia

2019-03-12T02:42:38Z (GMT) by PARIS CLARICE PAPAGIANIS
Bronchopulmonary dysplasia is a potentially fatal chronic lung disease that represents the principal cause of morbidity in infants born before 28 weeks of gestation. Both antenatal inflammation and mechanical ventilation are common antecedents that contribute to this condition. This thesis studies the effects of postnatal steroids or human amnion epithelial cells to treat and prevent brochopulmonary dysplasia. Our results suggest that tapered low-dose steroids reduces lung inflammation and injury, whilst hAECs improve lung morphology and have pro-reparative potential in lung pathology.